Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 28, 2026
Coca-Cola (KO) Q2 2026 Earnings Preview: Steady Growth Expected After +17.7% YTD Run

Coca-Cola (KO) Q2 2026 Earnings Preview: Steady Growth Expected After +17.7% YTD Run

Key Takeaways

  • The Coca-Cola Company (KO) is scheduled to report second quarter 2026 results on Tuesday, July 28, before the market opens, followed by a conference call at 8:30 a.m. ET.
  • Wall Street consensus points to earnings per share (EPS) of approximately $0.93 and revenue near $13.13 billion, representing year-over-year growth of roughly 7% and 4%, respectively.
  • Coca-Cola enters this report with strong momentum, having beaten consensus estimates in each of the last four quarters, including a 5.88% EPS surprise in Q1 2026.
  • Full-year 2026 guidance calls for 4% to 5% organic revenue growth and 8% to 9% comparable EPS growth, and investors will watch closely for any revisions to that outlook.
  • Key areas of focus include regional volume trends, pricing power, currency headwinds, and any commentary related to the ongoing Middle East conflict's impact on the Europe, Middle East & Africa (EMEA) segment.

Why Coca-Cola's Q2 Report Matters Right Now

Coca-Cola's Q2 2026 report arrives at a time when the company is firing on multiple cylinders. In Q1 2026, the Atlanta-based beverage titan delivered $12.47 billion in revenue — up 11.4% year over year — and EPS of $0.86, comfortably surpassing the $0.81 consensus. Organic revenue surged 10%, unit case volume rose 3%, and the operating margin expanded to 35.0%. These results reinforced confidence in Coca-Cola's all-weather strategy, which combines geographic diversification, pricing agility, and a portfolio spanning sparkling soft drinks, water, sports drinks, juice, dairy, and ready-to-drink coffee. With shares up roughly 17.7% year to date and the company recently extending its legendary dividend increase streak to 64 consecutive years, this earnings release will test whether Coca-Cola can sustain its growth trajectory amid evolving macroeconomic and geopolitical crosscurrents. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.

What Analysts Are Expecting for Q2

Analysts expect Coca-Cola to post Q2 2026 adjusted EPS of approximately $0.93, up from $0.87 in the year-ago quarter, representing roughly 7% growth. Revenue is forecast to land near $13.13 billion to $13.18 billion, a roughly 4% increase from $12.54 billion in Q2 2025. Jefferies projects a slightly higher adjusted EPS of $0.94 and organic sales growth of 3.9%, modestly above the broader Street estimate. Bank of America, which recently raised its price target to $95, expects total unit case volume growth of approximately 2%.

At the segment level, analysts are watching North America revenue of roughly $5.21 billion, EMEA revenue near $3.31 billion, Latin America around $1.73 billion, Asia Pacific at approximately $1.55 billion, and Bottling Investments near $1.49 billion. On profitability, non-GAAP operating income estimates include $1.64 billion for North America, $1.41 billion for EMEA, $1.07 billion for Latin America, and $652 million for Asia Pacific.

Coca-Cola's own full-year 2026 guidance, raised during the Q1 call, calls for organic revenue growth of 4% to 5% and comparable EPS growth of 8% to 9%, with a lower underlying effective tax rate of 19.9% providing a tailwind. Management has also signaled that concentrate shipments should realign more closely with unit case volumes during Q2, a dynamic investors will scrutinize carefully. From what I see, this alignment could be a key signal for the second half of the year.

How the Market Is Positioning Ahead of the Report

Investor sentiment heading into Coca-Cola's Q2 report leans decisively positive. The stock carries a consensus analyst rating of Moderate Buy, with 15 Buy ratings and a single Hold rating among Wall Street analysts, alongside an average 12-month price target near $88.30 to $88.44. Shares closed recently around $82 to $83, implying modest upside based on current targets. The company's dependable dividend, now $0.53 per quarter (approximately 2.5% annualized yield), and $477 million in Q1 share repurchases — with roughly $5.2 billion remaining under authorization — continue to attract income-oriented and total-return investors alike.

That said, risks are not absent. A revenue miss or disappointing volume figures could pressure the stock, particularly given its elevated valuation multiple and rich year-to-date gains. Currency fluctuations remain a persistent wildcard, as do geopolitical tensions in the Middle East, which could weigh on EMEA segment results. Any downward revision to full-year guidance would likely be met with a sharp negative reaction, while a guidance raise or strong volume print could extend the rally. I'm watching this closely for any signs of caution in the guidance.

Looking Ahead: Factors to Monitor Beyond Q2

Looking past the Q2 print, several factors will shape Coca-Cola's investment narrative through the remainder of 2026 and into 2027. The company's pricing power — the ability to pass through higher costs to consumers without meaningfully damaging demand — remains a critical watchpoint. In Q1, price/mix contributed positively across all regions, and investors will want to see that trend hold as inflation dynamics evolve globally.

Volume trends across key emerging markets also deserve attention. Latin America and parts of Asia Pacific have experienced weather-related disruptions and shifting consumer sentiment. Management's ability to pivot with localized strategies, affordable price-pack architectures, and targeted marketing will be essential to restoring momentum where softness emerges.

On the product side, Fairlife's continued expansion represents a significant growth catalyst. The high-protein dairy brand has been constrained by production capacity, and management has indicated that new capacity will ramp up through 2026. Any update on the timeline for debottlenecking Fairlife production could influence revenue growth expectations for the back half of the year. Coca-Cola Zero Sugar, which posted 14% volume growth in Q2 2025, also remains a product to watch as the company capitalizes on shifting consumer preferences toward zero-calorie options.

Finally, capital allocation strategy remains a cornerstone of the Coca-Cola investment case. With free cash flow guided to approximately $12.2 billion for 2026 — more than enough to cover the roughly $8.8 billion in dividends — the company has ample capacity for share buybacks, debt reduction, and selective acquisitions. Any commentary on the pace of buybacks or M&A appetite will be closely parsed by the investment community. One thing that stands out is how this positions the company for potential further capital returns.

Using AI Tools for Earnings Research

In preparing for earnings season, I find Tickeron's AI Screener helpful for quickly filtering stocks by industry, technical signals, and AI-generated metrics. It lets me compare names like KO against peers on volume trends and momentum without spending hours on manual work. This kind of tool has become a regular part of my process when evaluating reports like the one coming up.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KO

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


KO's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for KO moved out of overbought territory on July 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 instances where the indicator moved out of the overbought zone. In of the 40 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where KO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KO broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on KO as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KO just turned positive on July 28, 2026. Looking at past instances where KO's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KO advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 293 cases where KO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. KO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: KO's P/B Ratio (10.341) is slightly higher than the industry average of (5.764). P/E Ratio (26.081) is within average values for comparable stocks, (42.903). Projected Growth (PEG Ratio) (4.184) is also within normal values, averaging (4.589). Dividend Yield (0.024) settles around the average of (0.026) among similar stocks. KO's P/S Ratio (7.474) is slightly higher than the industry average of (2.926).

Notable companies

The most notable companies in this group are Coca-Cola Company (NYSE:KO), PepsiCo (NASDAQ:PEP).

Industry description

Non-alcoholic drinks include traces of alcohol or low alcohol content or without alcohol or alcohol removed. Functional Beverages, Carbonated Soft Drinks (CSDs), Sports Drinks, Fruit Beverages, and Bottled Water are some common types of non-alcoholic beverages. The largest segment in this market is soft drinks (think Pepsi and Coke). Many established companies in this space have also been stepping up production of low to zero-calorie varieties in recent years, to cater to a rising number of health-conscious consumers. Coca-Cola Company, Pepsico Inc, Keurig Dr Pepper Inc. and Monster Beverage Corporation are some major non-alcoholic beverage makers.

Market Cap

The average market capitalization across the Beverages: Non-Alcoholic Industry is 47.26B. The market cap for tickers in the group ranges from 1.77K to 373.68B. KO holds the highest valuation in this group at 373.68B. The lowest valued company is BVNNF at 1.77K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Non-Alcoholic Industry was -4%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -11%. BUDA experienced the highest price growth at 7%, while SUJA experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Beverages: Non-Alcoholic Industry was 78%. For the same stocks of the Industry, the average monthly volume growth was 61% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 65
Price Growth Rating: 60
SMR Rating: 61
Profit Risk Rating: 73
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
KO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of non-alcoholic beverages

Industry BeveragesNonAlcoholic

Profile
Details
Industry
Beverages Non Alcoholic
Address
One Coca-Cola Plaza
Phone
+1 404 676-2121
Employees
79100
Web
https://www.coca-colacompany.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Coca-Cola (KO) Q2 2026 Earnings Preview: Steady Growth Expected After +17.7% YTD Run